CA2727223C - Human .beta.3 adrenergic receptor ligand, and food or pharmaceutical product containing the same - Google Patents

Human .beta.3 adrenergic receptor ligand, and food or pharmaceutical product containing the same Download PDF

Info

Publication number
CA2727223C
CA2727223C CA2727223A CA2727223A CA2727223C CA 2727223 C CA2727223 C CA 2727223C CA 2727223 A CA2727223 A CA 2727223A CA 2727223 A CA2727223 A CA 2727223A CA 2727223 C CA2727223 C CA 2727223C
Authority
CA
Canada
Prior art keywords
receptor ligand
fatty acid
acid
beta
component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2727223A
Other languages
English (en)
French (fr)
Other versions
CA2727223A1 (en
Inventor
Yasuo Fujimoto
Shoichi Kurihara
Tadao Hamaya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ricom Corp
Original Assignee
Ricom Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ricom Corp filed Critical Ricom Corp
Publication of CA2727223A1 publication Critical patent/CA2727223A1/en
Application granted granted Critical
Publication of CA2727223C publication Critical patent/CA2727223C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CA2727223A 2008-06-11 2009-06-11 Human .beta.3 adrenergic receptor ligand, and food or pharmaceutical product containing the same Active CA2727223C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008153390 2008-06-11
JP2008-153390 2008-06-11
PCT/JP2009/060682 WO2009151094A1 (ja) 2008-06-11 2009-06-11 ヒトアドレナリンβ3受容体リガンド、これを含む食品及び医薬品

Publications (2)

Publication Number Publication Date
CA2727223A1 CA2727223A1 (en) 2009-12-17
CA2727223C true CA2727223C (en) 2014-10-07

Family

ID=41416798

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2727223A Active CA2727223C (en) 2008-06-11 2009-06-11 Human .beta.3 adrenergic receptor ligand, and food or pharmaceutical product containing the same

Country Status (7)

Country Link
US (1) US20110098358A1 (enExample)
EP (1) EP2316445A4 (enExample)
JP (2) JP5544660B2 (enExample)
KR (1) KR101274543B1 (enExample)
CN (1) CN102149375B (enExample)
CA (1) CA2727223C (enExample)
WO (1) WO2009151094A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2922552T3 (es) * 2014-11-03 2022-09-16 Nestle Sa Métodos que utilizan la temperatura facial para evaluar el impacto posterior a la ingestión de los ingredientes alimentarios en la oxidación de grasas
US9561206B2 (en) * 2015-01-07 2017-02-07 The United States Of America, As Represented By The Secretary Of The Navy Use of heptadecanoic acid (C17:0) to detect risk of and treat hyperferritinemia and metabolic syndrome
EP3661600A4 (en) 2017-10-23 2021-08-11 Epitracker, Inc. FATTY ACID ANALOGS AND ITS USE IN THE TREATMENT OF DISEASES RELATED TO METABOLISM SYNDROME
AU2019274431B2 (en) 2018-05-23 2025-03-13 Epitracker, Inc. Compositions and methods for diagnosis and treatment of conditions related to the quality of aging and longevity
EP3908374A4 (en) 2019-01-09 2022-12-28 Epitracker, Inc. COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES
JP7404382B2 (ja) 2019-03-04 2023-12-25 エピトラッカー インコーポレイテッド 脂肪酸アナログ、ならびに認知機能障害、行動症状および慢性疼痛の処置におけるそれらの使用
JP7500037B2 (ja) * 2019-07-24 2024-06-17 国立大学法人 東京大学 血中尿酸値低下剤及び血中尿酸値低下用食品組成物
WO2023080939A1 (en) 2021-11-03 2023-05-11 Epitracker, Inc. Pentadecanoylcarnitine for treatment of conditions related to the quality of aging and longevity

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2173545C (en) * 1995-04-07 2004-06-29 Kalyana Sundram Increasing the hdl level and the hdl/ldl ratio in human serum by balancing saturated and polyunsaturated dietary fatty acids
US5578334A (en) * 1995-04-07 1996-11-26 Brandeis University Increasing the HDL level and the HDL/LDL ratio in human serum with fat blends
EP1285590A1 (en) * 2001-08-08 2003-02-26 Société des Produits Nestlé S.A. Lipid blends
RU2305547C2 (ru) * 2001-08-23 2007-09-10 Вестгейт Байолоджикал Лимитед Применение апопротеинов сыворотки молока в профилактике или лечении микробной или вирусной инфекции
EP1508335B1 (en) * 2002-05-27 2011-09-28 Morinaga & Co. Ltd. Compositions comprising a cocoa fraction for use in the treatment of periodontitis caused by bacteria belonging to genus porphyromonas, prevotella, fusobacterium or actinobacillus
JP2004075653A (ja) * 2002-06-19 2004-03-11 Nisshin Oillio Ltd 体脂肪分解促進剤および飲食物
WO2004022049A1 (ja) * 2002-09-05 2004-03-18 The Nisshin Oillio Group, Ltd. 痩身剤およびその飲食物
AU2003261928A1 (en) * 2002-09-05 2004-03-29 The Nisshin Oillio Group, Ltd. Agents, foods and drinks controlling lipid metabolism
JP5102435B2 (ja) 2002-10-08 2012-12-19 株式会社リコム キトサン含有多糖、その製造方法及び用途
JP2006096666A (ja) 2002-10-31 2006-04-13 Kaneka Corp 選択的ヒトβ３アドレナリン受容体アゴニスト剤
JP2005015358A (ja) * 2003-06-25 2005-01-20 Pharma Design Inc 摂食障害の治療に供される医薬組成物
US20080146657A1 (en) * 2003-11-04 2008-06-19 Hiroshi Tsuboi Plant-Origin Alpha3-Adrenoceptor Agonist and Use of the Same
JP2005179264A (ja) * 2003-12-19 2005-07-07 Shokubutsu Kogaku Kenkyusho:Kk 体重増加抑制剤
US20060084637A1 (en) * 2004-10-18 2006-04-20 Maria Alemany Methods of using fatty-acid esters of estrogens and thermogenic compounds for reducing the body weight of a mammal and compositions containing the same
US20080200707A1 (en) * 2005-01-04 2008-08-21 Mochida-Pharmaceuticals Pharmaceutical Co., Ltd. Lipotoxicity Relieving Agent
CA2593768C (en) * 2005-01-04 2014-02-18 Mochida Pharmaceutical Co., Ltd. Use of .omega.3 unsaturated fatty acids for relieving lipotoxicity
GB0514463D0 (en) * 2005-01-31 2005-08-17 Loders Croklaan Bv Use of pinolenic acid
WO2008000440A1 (en) * 2006-06-27 2008-01-03 Lipid Nutrition B.V. Use of a polyunsaturated fatty acid compound

Also Published As

Publication number Publication date
CN102149375B (zh) 2015-09-30
JPWO2009151094A1 (ja) 2011-11-17
CN102149375A (zh) 2011-08-10
EP2316445A1 (en) 2011-05-04
EP2316445A4 (en) 2011-12-21
CA2727223A1 (en) 2009-12-17
JP2014080432A (ja) 2014-05-08
KR101274543B1 (ko) 2013-06-17
JP5544660B2 (ja) 2014-07-09
US20110098358A1 (en) 2011-04-28
WO2009151094A1 (ja) 2009-12-17
KR20110017437A (ko) 2011-02-21

Similar Documents

Publication Publication Date Title
CA2727223C (en) Human .beta.3 adrenergic receptor ligand, and food or pharmaceutical product containing the same
KR101665001B1 (ko) ２­옥소­１­피롤리딘 유도체를 포함하는 약학적 조성물
JP2014507411A (ja) 骨及び関節の成長、回復、及び維持の促進のための食事サプリメント
NZ620887A (en) A novel formulation of diclofenac
CN102586119A (zh) 一种功能红曲菌株及其功能青稞红曲制备方法和应用
EP3325094A1 (en) Compositions comprising 15-hepe for use in treating or preventing cancer and neurologic disease
DE102017105036A1 (de) Mittel zur Anwendung bei der Behandlung der Dyslipidämie
JP6145352B2 (ja) 納豆菌を用いたマコンブ発酵物の血圧上昇抑制剤
JP2010270111A (ja) アルギニン含有錠剤
HK1157216A (en) Human b3 adrenergic receptor ligand, and food or pharmaceutical product containing the same
JP2014172903A (ja) Ｌａｃｔｏｂａｃｉｌｌｕｓｐｌａｎｔａｒｕｍを用いたアカモク発酵物の血圧上昇抑制剤
DE10305661A1 (de) Darreichungsform zur Kolon-spezifischen Wirkstofffreisetzung
US20100028465A1 (en) Composition for ameliorating cerebral function
DE602004002292T2 (de) Zusammensetzungen enthaltend eine superoxiddismutase, einen 5-lipoxygenase-inhibitor sowie deren verwendung
JP6145353B2 (ja) Ｌａｃｔｏｂａｃｉｌｌｕｓ属を用いた発酵ヒダカコンブの血圧上昇抑制剤
JP4594489B2 (ja) 特異的殺癌細胞剤及びこれを配合してなる組成物
JP2019172614A (ja) 遺伝子発現制御剤及び筋委縮の抑制剤、予防剤又は改善剤
EP2316432A1 (de) Zusammensetzung enthaltend Fesoterodin und Ballaststoffe
EP1915142A1 (en) Composition comprising oleic acid and the use thereof
JP2010095456A (ja) 脂質代謝改善剤
JP6306213B2 (ja) キサンタンガムとアカシアガムとの共顆粒物
CN103861105A (zh) 含中药三七和降脂药他汀类组成的复方制剂及其制备方法
WO2020028129A1 (en) Cardioprotective amino acid formulations
JP2010059106A (ja) 糖尿病進行抑制作用を有する組成物
Katoh et al. T. Nabeshima1, 2, M. Hiramatsu2, T. Koide2, S. Ishihara2, A.

Legal Events

Date Code Title Description
EEER Examination request